Selective destruction of cells infected with human immunodeficiency virus
Abstract
Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.
- Inventors:
- Issue Date:
- Research Org.:
- Idaho National Laboratory (INL), Idaho Falls, ID (United States)
- Sponsoring Org.:
- USDOE
- OSTI Identifier:
- 1174512
- Patent Number(s):
- 6627197
- Application Number:
- 09/785,921
- Assignee:
- Bechtel BWXT Idaho, LLC (Idaho Falls, ID)
- Patent Classifications (CPCs):
-
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Y - NEW / CROSS SECTIONAL TECHNOLOGIES Y10 - TECHNICAL SUBJECTS COVERED BY FORMER USPC Y10S - TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- DOE Contract Number:
- AC07-94ID13223
- Resource Type:
- Patent
- Country of Publication:
- United States
- Language:
- English
- Subject:
- 59 BASIC BIOLOGICAL SCIENCES
Citation Formats
Keener, William K., and Ward, Thomas E. Selective destruction of cells infected with human immunodeficiency virus. United States: N. p., 2003.
Web.
Keener, William K., & Ward, Thomas E. Selective destruction of cells infected with human immunodeficiency virus. United States.
Keener, William K., and Ward, Thomas E. Tue .
"Selective destruction of cells infected with human immunodeficiency virus". United States. https://www.osti.gov/servlets/purl/1174512.
@article{osti_1174512,
title = {Selective destruction of cells infected with human immunodeficiency virus},
author = {Keener, William K. and Ward, Thomas E.},
abstractNote = {Compositions and methods for selectively killing a cell containing a viral protease are disclosed. The composition is a variant of a protein synthesis inactivating toxin wherein a viral protease cleavage site is interposed between the A and B chains. The variant of the type II ribosome-inactivating protein is activated by digestion of the viral protease cleavage site by the specific viral protease. The activated ribosome-inactivating protein then kills the cell by inactivating cellular ribosomes. A preferred embodiment of the invention is specific for human immunodeficiency virus (HIV) and uses ricin as the ribosome-inactivating protein. In another preferred embodiment of the invention, the variant of the ribosome-inactivating protein is modified by attachment of one or more hydrophobic agents. The hydrophobic agent facilitates entry of the variant of the ribosome-inactivating protein into cells and can lead to incorporation of the ribosome-inactivating protein into viral particles. Still another preferred embodiment of the invention includes a targeting moiety attached to the variants of the ribosome-inactivating protein to target the agent to HIV infectable cells.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2003},
month = {9}
}
Works referenced in this record:
Ricin: structure, mode of action, and some current applications.
journal, February 1994
- Lord, J. M.; Roberts, L. M.; Robertus, J. D.
- The FASEB Journal, Vol. 8, Issue 2
Preparation and characterization of recombinant proricin containing an alternative protease-sensitive linker sequence
journal, September 1992
- Westby, Michael; Argent, Richard H.; Pitcher, Carol
- Bioconjugate Chemistry, Vol. 3, Issue 5
Rationale for the Use of Immunotoxins in the Treatment of HIV-infected Humans
journal, January 1998
- Van Oijen, Monique G. C. T.; Preijers, Frank W. M. B.
- Journal of Drug Targeting, Vol. 5, Issue 2
Bryodin, a single-chain ribosome-inactivating protein, selectively inhibits the growth of HIV-1-infected cells and reduces HIV-1 production
journal, December 1993
- Wachinger, Michael; Samtleben, Rainer; Gerhäuser, Clarissa
- Research in Experimental Medicine, Vol. 193, Issue 1
HIV-infected cells are killed by rCD4-ricin A chain
journal, November 1988
- Till, M.; Ghetie, V.; Gregory, T.
- Science, Vol. 242, Issue 4882
Recombinant proricin binds galactose but does not depurinate 28 S ribosomal RNA
journal, September 1989
- Richardson, Peter T.; Westby, Michael; Roberts, Lynne M.
- FEBS Letters, Vol. 255, Issue 1
Human Immunodeficiency Virus Protease Inhibitors
journal, June 1997
- Redshaw, S.; Thomas, Gj
- Emerging Drugs, Vol. 2, Issue 1